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Abstract The recognition of the importance of the Wnt-
signaling pathway in bone metabolism and studies of
patients with rare skeletal disorders characterized by high
bone mass identified sclerostin as target for the develop-
ment of new therapeutics for osteoporosis. Findings in
animals and humans with sclerostin deficiency as well as
results of preclinical and early clinical studies with scle-
rostin inhibitors demonstrated a new treatment paradigm
with a bone building agent for the management of patients
with osteoporosis, the antifracture efficacy, and long-term
tolerability of which remain to be established in on-going
phase III clinical studies. In this article we review the
currently available preclinical and clinical evidence sup-
porting the use of sclerostin inhibitors in osteoporosis.
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Introduction
Available pharmacological agents for the treatment of
osteoporosis reduce the risk of fractures but cannot restore
the low mass and the deteriorated architecture of the
skeleton of patients with severe disease. These agents
reduce bone fragility by correcting the imbalance between
bone resorption and bone formation by either decreasing
bone resorption (e.g., bisphosphonates, denosumab) or
stimulating bone formation (e.g., PTH peptides, PTHrP
analogs) by different molecular mechanisms of action.
Reduction of bone resorption, though essential for the
maintenance or improvement of bone strength, cannot
replace already lost bone. For this, specific stimulation of
bone formation is required. Thus, in theory, optimal
pharmacological management of osteoporosis should aim
at decreasing bone resorption and stimulating bone for-
mation at all skeletal envelopes. Such approach will not
only prevent the structural decay of bone tissue but will
also substantially increase bone mass leading to enhanced
reduction of the risk of fractures particularly at sites with
predominant cortical bone.
A mechanistic study examined this hypothesis and tes-
ted the effect of daily injections of teriparatide together
with 6-monthly injections of denosumab in women with
postmenopausal osteoporosis [1]. This combination, that
allows continuous stimulation of bone formation by teri-
paratide by blocking its concurrent stimulating effect on
bone resorption by denosumab, increased spine and hip
BMD to levels significantly higher than either monother-
apy after 1 year. While the study, by design, did not pro-
vide any evidence of improved antifracture efficacy of the
combination therapy, results obtained with High-Resolu-
tion pQCT of the distal tibia suggested that it may have a
better effect than either teriparatide or denosumab on the
biomechanical competence of bone [2]. The discovery of
the importance of the Wnt-signaling pathway in bone
metabolism [reviewed in 3] and studies of patients with
rare skeletal disorders characterized by high bone mass
identified sclerostin—a natural inhibitor of the Wnt path-
way that reduces bone formation—as a target for the
development of new therapeutics that may fulfill the
requirements for improved treatment for osteoporosis [4–
6]. In this article we review the currently available pre-
clinical and clinical evidence supporting the use of
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sclerostin inhibitors in the management of patients with
osteoporosis.
Sclerostin Deficiency
Sclerosteosis and van Buchem disease are two rare, auto-
somal recessive, sclerosing bone disorders characterized by
high bone mass and increased bone strength caused by
defects of the SOST gene in chromosome 17q12-21 that
encodes sclerostin [7–12]. While sclerosteosis is caused by
inactivating mutations of SOST, a 52 kb homozygous
noncoding deletion 35 kb downstream of the SOST gene
containing a regulatory element for SOST transcription is
the cause of van Buchem disease. These defects lead to
impaired synthesis of sclerostin, a secreted glycoprotein
with sequence similar to the DAN (differential screening-
selected gene aberrative in neuroblastoma) family of pro-
teins. Sclerostin is secreted by mature osteocytes embedded
in the mineralized matrix and inhibits bone formation at the
bone surface by binding to LRP5/6 co-receptors and
thereby antagonizing canonical, beta-catenin dependent,
Wnt signaling in osteoblasts [13–17]. Sclerostin binds to
the first propeller of the LRP5/6 receptor and disables the
formation of complexes of Wnts with frizzled receptors
and the co-receptors LRP5/6, an action facilitated by the
LRP4 receptor [18–20] (Fig. 1). Moreover, sclerostin acts
on neighboring osteocytes and increases RANKL expres-
sion and the RANKL/OPG ratio and thereby stimulates
osteoclastic bone resorption having, thus, a catabolic effect
in bone in addition to its negative effect on bone formation
[21, 22]. The clinical, biochemical, and radiological fea-
tures of sclerosteosis and van Buchem disease have been
described in detail [23–31] and we will further discuss only
features of these diseases that may assist in the interpre-
tation of results obtained in preclinical and clinical studies
of sclerostin inhibition.
Targeted deletion of the SOST gene in mice greatly
increased mineral density of vertebrae and whole leg, as
well as the volume and strength of both trabecular and
cortical bone [32]. MicroCT analysis showed, in addition,
significant increases in the thickness of the distal femur and
of the cortical area of the femur shaft due to increased rates
of bone formation, assessed by histomorphometry, at tra-
becular and cortical (endosteal and periosteal) compart-
ments while osteoclast surface was not different from that
of wild-type animals; for example, compared with wild-
type female mice, mineralizing surfaces, mineral apposi-
tion rate, and bone formation rate of the periosteal surface
of cortical bone of SOST-KO mice increased by 249, 143,
and 396 %, respectively. Bone had normal lamellar struc-
ture and, similar to humans with sclerosteosis, the
increased mineral density was not associated with
Fig. 1 Schematic presentation of the canonical Wnt-signaling path-
way and of the effect of sclerostin on bone cells. a Wnts bind to the
receptor complex of frizzled (FZD) and LRP5/6, prevent the
degradation of beta-catenin, and increase its accumulation in the
cytoplasm; beta-catenin is translocated to the nucleus where it
associates with transcription factors to control transcription of target
genes in osteoblasts. b Osteocyte-produced sclerostin is transported to
the bone surface and acts on osteoblasts to reduce bone formation by
disabling the association of Wnts with their co-receptors and
inhibiting the Wnt pathway in osteoblasts, an action facilitated by
LRP4; sclerostin also stimulates the production of RANKL by
neighboring osteocytes and osteoclastic bone resorption
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increased bone matrix mineralization [33]. These findings
are clearly different from those observed in animal models
of osteopetrosis with high mineral density. As in patients
with sclerosteosis and van Buchem disease, serum calcium
and phosphate concentrations in SOST-KO mice were not
different from those of their wild-type littermates while
serum osteocalcin values were increased with no changes
in serum TRAP5b values. Follow-up of these mice showed
that BMD increased progressively from 1 to 4 months of
age and at a slower rate thereafter reaching a peak that was
maintained up to 18 months [4]. It should be noted that in
patients with sclerosteosis and van Buchem disease the
disease stabilizes after the 3rd decade of life and no new
complications resulting from continuing bone overgrowth
are generally observed. Importantly, SOST-KO mice had
no apparent extraskeletal abnormalities.
The restricted expression of sclerostin in bone and the
lack of complications in organs other than the skeleton in
humans and animals with sclerostin deficiency made this
protein an attractive target for the development of a novel
anabolic therapy for osteoporosis. This notion was further
supported by findings in human heterozygous carriers of
sclerosteosis who have decreased serum sclerostin levels
associated with high normal or increased BMD and
increased bone strength without any clinical signs or
complications of the disease [27, 28] indicating that scle-
rostin production can be reduced without any adverse
skeletal effects.
Preclinical Studies with Sclerostin Inhibitors
To assess the effects of sclerostin inhibition on bone
metabolism and strength neutralizing antibodies to scle-
rostin (Scl-Ab) were administered to different animal
models for varying periods of time (Table 1). In an early
study, Scl-Ab was given subcutaneously twice-weekly for
5 weeks to rats ovariectomized (OVX) at the age of
6 months and left untreated for 1 year [34]. Treatment of
this rodent model of osteoporosis was associated with
dramatic increases in bone mass and improvement in bone
strength at all skeletal sites examined. Remarkably, this
short-term treatment with Scl-Ab not only completely
reversed OVX–induced bone loss, but increased bone mass
and strength to levels greater than those of sham-operated
control animals. Histologically, bone formation increased
markedly in trabecular, endocortical, and periostal surfaces
leading to increases in trabecular and cortical thickness and
reduction of cortical porosity. Increases in both mineral
apposition rate and mineralizing surfaces suggested that
short exposure to sclerostin inhibitor increases both the
activity and the number of osteoblasts. The anabolic effect
of Scl-Ab in rodents did not appear to depend on the
prevalent rate of bone turnover and was not affected by
pretreatment or co-treatment with alendronate of OVX rats
with osteopenia [35]. Differently from PTH/PTHrP pep-
tides, the high bone-forming activity of Scl-Ab was not
associated with an increase in bone resorption. Instead a
decrease of osteoclast surface was observed, suggesting a
functional uncoupling between bone formation and bone
resorption, as also observed in the studies of the SOST-KO
mice. The effect of Scl-Ab on bone formation was rever-
sible upon discontinuation of treatment. Similar results on
both trabecular and cortical bone mass were generally
observed in other rodent models treated with Scl-Ab (e.g.,
10-month-old intact female rats immediately after OVX,
OVX rats with established osteopenia, aged male rats,
orchidectomized male rats, mouse models of immobiliza-
tion, glucocorticoid-treated mice, and mice models of
osteogenesis imperfecta) [4, 36–43]. Treatment with Scl-
Ab was also reported to increase bone formation, mass and
strength at the site of fracture in animal models of fracture
healing [4, 44–46], and to completely reverse the bone loss
and the deterioration of several bone mechanical and
microstructural properties in a mouse model of chronic
colitis [47]. Finally, despite marked increases in bone
volume with Scl-Ab, matrix mineralization was not affec-
ted indicating that treatment does not negatively impact
bone matrix quality [48].
Treatment of intact female cynomolgus monkeys with
two once-monthly subcutaneous injections of different
doses of Scl-Ab induced dose-dependent increases in bone
formation on trabecular, periosteal, endocortical, and
intracortical surfaces associated with significant gains in
BMC/BMD [49]. Serum P1NP levels peaked 2 weeks after
the first injection and 1 week after the second injection
returning to baseline at the end of the treatment interval.
There was no clear effect of Scl-Ab treatment on the bone
resorption marker serum CTX. Biomechanical testing
demonstrated a highly significant increase in the strength of
vertebrae of animals treated with two injections of Scl-Ab
compared with vehicle-treated animals while bone strength
of the femoral diaphysis increased but not significantly. At
both sites strong correlations between bone mass and bone
strength were observed indicating that the changes in bone
strength were due to the induced increases in bone mass.
Thus, short-term exposure of different animal models to
Scl-Ab was associated with remarkable changes of bone
homeostasis, mass, and strength. Such changes occurred at
all skeletal compartments and demonstrated that bone
formation and resorption can be modulated in opposite
directions by an inhibitor of sclerostin.
Two studies provided insight into the long-term use and
the mechanism of action of Scl-Ab on bone metabolism.
The first study, examined the effect of weekly injections of
Scl-Ab given to 6-month-old OVX rats with osteopenia for
26 weeks. BMD of the spine and the tibia increased
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progressively through 26 weeks of treatment and was
associated with increases in trabecular and cortical bone
mass and strength at multiple skeletal sites [50]. Lumbar
trabecular and endocortical and periosteal bone formation
rates increased and peaked at 6 weeks of treatment with a
gradual decline thereafter while osteoclast surface and
eroded surface were significantly lower in Scl-Ab-treated
OVX animals than in controls at all time points. These
important observations reveal that while the early gains of
bone mass with Scl-Ab treatment are due to the strong
stimulation of bone formation combined with reduced
osteoclastic activity, later gains may be attributed to per-
sistently lower osteoclast activity and closure of the
remodeling space combined with residual stimulation of
osteoblasts at trabecular and endocortical surfaces. This
study provides important, yet intriguing, information about
the long-term effects of treatment with sclerostin inhibitors
and raises questions about potential bone-site specificity of
treatment in the long term as well as of optimal duration of
treatment of humans with osteoporosis with Scl-Ab.
To further characterize the specific effects of Scl-Ab on
bone metabolism, the second study examined bone biopsies
from OVX rats and intact male cynomolgus monkeys
treated with Scl-Ab for 5 and 10 weeks, respectively [51].
Results showed that the majority of new bone formation
was modeling based, occurring at quiescent surfaces
(Fig. 2), and was associated with constant reduction of
bone resorption. Treatment increased the rate of activation
of new modeling surfaces while it decreased the rate of
activation of bone remodeling surfaces and extended the
formation period of existing remodeling sites. These
observations support the notion of a new treatment
paradigm for osteoporosis in line with the theoretical
considerations discussed in Introduction and compatible
with a true anabolic response ([52]; Fig. 3). We have
previously suggested that agents that stimulate bone for-
mation should be distinguished into bone forming (e.g.,
teriparatide) and anabolic [53]. The results of this study
illustrate the differences in mechanism of action between
the two classes of bone formation-stimulating agents at the
bone tissue level, the clinical relevance of which remains to
be established in the on-going human studies.
Clinical Studies with Sclerostin Inhibitors
Information about three sclerostin inhibitors, all mono-
clonal humanized neutralizing antibodies, are currently in
the public domain [romosozumab or AMG 785 (Amgen
and UCB), blosozumab (Elli Lilly), and BPS804
(Novartis)].
The first human, placebo-controlled, study of 72 healthy
men and postmenopausal women, demonstrated a dissoci-
ation of bone turnover marker responses following single
subcutaneous or intravenous injections of romosozumab
[54]. With the highest dose used (10 mg/kg sc), the bone
formation markers serum P1NP, BAP, and osteocalcin
increased rapidly and progressively reaching peaks of 184,
126, and 176 % of baseline values, respectively, after about
30 days and returned to baseline after about 2 months. In
contrast, the bone resorption marker, serum CTX,
decreased by a maximum 54 % of baseline values about
14 days after the antibody injection and returned to base-
line after 2 months. This early response to a single injection
of romosozumab is in agreement with the uncoupling of
Table 1 Biomechanical
competence of bones (strength)
of animals treated with
sclerostin antibody
Animal Age Treatment Duration Strength Ref.
Intact gonads
Rats (M) 6 month Scl-AbVI 2/week 9 week :F, V(nd) [64]
Rats (M) 7 month Scl-AbIII 2/week 7 week :V/F [46]
Rats (M) 16 month Scl-AbII 2/week 5 week :V/F [37]
Cynos (Fe) 3–5 years Scl-AbIV 1/month 2 week :V$F [49]
Cynos (M) 4–5 years Scl-AbV 2/week 10 week :V/F [46]
Estrogen deficiency (OVX)
Rats 18 montha Scl-AbII 2/week 5 week :V/F [34]
Rats 6 monthb Scl-AbVI 1/wh 26 week :V/F [50]
Rats 6.5 monthc Scl-A III 1/week 6 week :V, F(nd) [35]
Cynos C9 years ROMO 1/weekd 12 month :V/F [65]
Cynos cynomolgus monkeys, Scl-Ab sclerostin antibody, ROMO romosozumab, V vertebra, F femur, nd not
examined
a OVX at 6 months
b OVX at 4 months
c OVX at 3.5 month
d Start treatment 4 month after OVX
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osteoblast and osteoclast activities observed in the animal
studies. BMD of lumbar spine and total hip increased
significantly by 5.3 and 2.8 %, respectively, on day 85. The
pharmacodynamic response of different doses of romoso-
zumab, up to three sc injections, given once-monthly to
postmenopausal women and men with low bone mass was
consistent with the results of the single-dose study showing
early increases in bone formation markers and decreases in
serum CTX [55]. In a subset of subjects of this study,
changes of vertebral trabecular and cortical bone were
examined by QCT and HR-QCT of the spine at 3 and
6 months, respectively. Compared with placebo, romoso-
zumab treatment resulted in rapid improvements in tra-
becular and cortical bone mass and structure as well as of
whole bone stiffness. These gains were maintained or
improved in the 3 months following administration of the
last dose of romosozumab. Improvements were also
observed in microstructural aspects of both trabecular and
cortical bone [56].
In a study of similar design, single or multiple doses of
blosozumab given either subcutaneously or intravenously
for up to 8 weeks to postmenopausal women, aged between
40 and 80 years, increased lumbar spine BMD dose-de-
pendently, up to 7.7 % after 85 days; total hip BMD did
not change significantly after either single or multiple
doses of blosozumab [57]. There were dose-dependent
changes of bone turnover markers of similar magnitude and
direction as those observed with romosozumab. No serious
adverse effects were observed with either sclerostin
inhibitor.
The efficacy and tolerability of romosozumab was
examined in a phase II study of 419 postmenopausal
women, aged 55–85 years with BMD T-scores between
\-2.0 and -3.5 [58]. In this study, different doses and
dosing intervals of subcutaneous injections of romosozu-
mab were compared with placebo, oral alendronate 70 mg
weekly, and subcutaneous teriparatide 20 lg daily. All
women received calcium and vitamin D supplements and
were randomly assigned to receive subcutaneous injections
of placebo or romosozumab either once-monthly (70, 140,
210 mg) or once every 3 months (140, 210 mg). The pri-
mary efficacy point of the study was the change of spine
BMD after 12 months. Three hundred and eighty-three
(91 %) participants completed the study protocol. All doses
of romosozumab induced significant gains in BMD. The
highest dose of romosozumab used, 210 mg once-monthly,
increased BMD at the spine (11.3 %), total hip (4.1 %),
and femoral neck (3.7 %) after 1 year. These increases
were significantly higher than those observed in women
treated with either alendronate or teriparatide (Fig. 4). No
statistically significant differences in BMD of the distal
radius were observed between any of the three treatment
groups and placebo. Markers of bone formation increased
1 week after the initial injection of romosozumab and
reached a peak after 1 month. Thereafter, they decreased
progressively returning to baseline values between 2 and 9
Fig. 2 Upper panel Trabecular
surfaces (L2) of OVX rats
treated with vehicle or Scl-Ab.




(QS) or osteoclastic (OCs), and
expressed as % of the total
surface. Lower panel
Endocortical surfaces (proximal
diaphysis) of male cynomolgus
monkeys. Bone surfaces are
characterized as modeling-
based bone formation (MBF),
remodeling-based bone
formation (RBF), quiescent
(QS) or eroded surfaces (ES),
and expressed as % of the total
surface. (From Ref. [51])
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months of treatment reaching values significantly lower
than baseline at 12 months. As in the phase I study, serum
CTX levels decreased early after the first injection to a
nadir of about 50 % of baseline after 15 days returning to
baseline at 3 months and decreasing again significantly to
-26 % of baseline at 12 months. These results illustrate
that the action of sclerostin inhibitor on bone turnover is
different from that of teriparatide as was already suggested
in the animal and phase I human studies as well as in the
observed changes of bone turnover markers in other clin-
ical studies with teriparatide ([59]; Fig. 5). The incidence
of adverse events was similar among all groups of studied
women with the exception of mild reactions at the injection
sites of romosozumab. One patient treated with romoso-
zumab was diagnosed with breast cancer during the trial
that was not considered to be treatment related. Antibodies
with in vitro neutralizing activity were detected in 3 % of
patients on romosozumab that had no effect on treatment
outcomes. Continuation of romosozumab treatment
210 mg once-monthly for a second year increased further
spine and total hip BMD to total gains of 15.2 and 5.5 %,
respectively. The slope of this increase was, however,
different from that during the first year of treatment [60].
Women were then randomized to receive denosumab or
placebo for an additional year. Women who transitioned to
denosumab continued to accrue BMD at a rate similar to
that with romosozumab during the second year to a total of
19.4 % at the spine and 7.1 % at the total hip, while in
those who transitioned to placebo BMD returned towards
pretreatment levels. Interestingly, during the second year of
romosozumab treatment serum levels of both P1NP and
CTX remained below baseline indicating continuous
stable decrease of bone turnover with prolongation of
treatment. In patients who were switched to denosumab
Fig. 3 Bone remodeling and modeling under physiological condi-
tions, in osteoporosis, and during treatment with sclerostin inhibitors.
a Within an active BMU bone is constantly removed by osteoclasts
(OCs) and new bone matrix is produced by osteoblasts (OBs), at sites
where bone resorption has occurred with the amount of bone formed
being equal to the amount of bone resorbed. Once the BMU is
completed, osteoblasts become entrapped as osteocytes (OCYs) into
the newly formed matrix, remain on the bone surface as lining cells
(LCs), or undergo apoptosis. Bone then remains in the quiescent
phase until a new BMU is initiated. b In osteoporosis, bone resorption
is increased and bone formation is decreased, resulting in a loss of
bone. c Inhibition of osteocyte-produced sclerostin decreases bone
resorption but mostly increases both remodeling-based and modeling-
based bone formation, thereby causing a striking increase in bone
formation, particularly in areas that were not previously resorbed
(modeling). (Modified from original Fig. 1 of Ref. [52])
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bone turnover markers decreased further to levels previ-
ously described with this antibody while in those who
discontinued treatment serum P1NP levels gradually
returned to pretreatment values and serum CTX levels,
after an initial increase above baseline, gradually returned
towards pretreatment values [60]. The pattern of changes of
serum CTX values following romosozumab discontinua-
tion was similar to that observed after discontinuation of
denosumab [61]. Although the magnitude of these changes
was different, due to the different degrees of suppression of
bone resorption by the two treatments, levels of peak
increases above baseline values were very similar illus-
trating that romosozumab has a genuine antiresorptive
action and support the notion that this is exerted by a
RANKL-dependent mechanism. Phase III clinical studies
with fracture endpoints are currently performed with
romosozumab.
The results of a dose-finding study of blosozumab were
recently reported [62]. One hundred and twenty post-
menopausal women aged 45–85 years with BMD T-scores
between -2.0 and -3.5 were included in the study and 106
completed 1 year of treatment. All women received calcium
and vitamin D supplements and were randomized to receive
placebo or blosozumab subcutaneously 180 mg every
4 weeks, 180 mg every 2 weeks, or 270 mg every 2 weeks.
Blosozumab treatment induced dose-dependent increases in
lumbar spine BMD of 8.4, 14.9, and 17.0 %, in total hip
BMD of 2.1, 4.5, and 6.3 %, and in femoral neck BMD by
2.7, 3.9, and 6.3 %, respectively. Total body bone mineral
content increased also dose-dependently after 1 year; blo-
sozumab treatment had no effect on BMD of the distal
radius. Mild injection site reactions were more frequently
observed with blosozumab than with placebo and antibodies
to blosozumab developed in 32 patients (35 %) in one of
whom these antibodies were neutralizing and reduced her
response to treatment. Although the frequency of adverse
events was similar among all groups, four women (all
Japanese) treated with blosozumab were diagnosed with
breast cancer between 3 months after start of treatment to
1 year after the last dose of the antibody while no cases of
breast cancer were reported in the placebo-treated women.
These were not considered to be related to treatment. To
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Fig. 4 Percent changes of lumbar spine and total hip BMD during
treatment of postmenopausal women with low bone mass with
romosozumab (ROMO) 210 mg once-monthly sc, teriparatide
(TPTD) 20 lg daily sc, alendronate (ALN) 70 mg once-weekly
orally, or placebo. a = p\ 0.05 between ROMO and placebo,
b = p\ 0.02 between ROMO and ALN, c = p\ 0.02 between
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Fig. 5 Schematic presentation of changes in the levels of serum
biochemical markers of bone formation (P1NP) and bone resorption
(CTX) during treatment with subcutaneous injections of either
romosozumab 210 mg once-monthly or teriparatide 20 lg daily for
1 year. (From Ref. [59]; original data for romosozumab from Ref.
[58] and for teriparatide from Ref. [66])
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BMD and bone turnover markers, the 106 women who
completed the first year of the study were followed for an
additional year without treatment; eighty-eight women
completed the study [63]. Following discontinuation of
blosozumab, spine and hip BMD decreased progressively
with similar rates for all doses reaching values that depended
on the peak values achieved on treatment after 1 year
(Fig. 6). For example, in women treated with the highest
dose of blosozumab BMD values were still significantly
higher than baseline values. Conversely, in women treated
with the lowest dose of blosozumab BMD values returned to
baseline after 1 year. Bone turnover markers showed no
particular changes and remained around baseline values
with small but significant increases in serumCTXwith some
but not all doses of blosozumab. There is no information
about on-going phase III clinical studies with blosozumab
(www.clinicaltrials.gov).
No results have been communicated yet with the use of
BPS804 but a randomized, double-blind, placebo-con-
trolled, phase II study evaluating the safety and efficacy of
multiple-dosing regimens of BPS804 in postmenopausal
women aged 45–85 years with baseline lumbar spine
T-score between -2.0 to -3.5 was completed in 2015
(www.clinicaltrials.gov).
Clinical Perspective
The results of the preclinical and early clinical studies with
sclerostin inhibitors demonstrate a new treatment paradigm
with a bone building agent for the management of patients
with osteoporosis, the antifracture efficacy, and long-term
tolerability of which remain to be established in the on-
going phase III clinical studies. The findings in animals and
humans with sclerostin deficiency as well as the docu-
mented kinetics of bone remodeling/modeling and bone
mass in response to sclerostin inhibitors though clearly
indicative of a novel mechanism of action, do not yet allow
an accurate estimate of the optimal duration of treatment.
Osteoporosis is a chronic disease requiring chronic treat-
ment and it is not yet known whether long-term treatment
with a sclerostin inhibitor will be associated with a sus-
tained anabolic effect on bone or whether initial treatment
need to be followed by another agent. The latter approach
seems more likely and currently available data suggest that
this may be preferred for the pharmacological management
of patients with severe osteoporosis in the future.
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